Psychiatric neural networks and neuropharmacology: Selected advances and novel implications

Saudi Pharmaceutical Journal

Volumn 22, Issue 2, 2014, Pages 95-100

  Ghanemi, Abdelaziz ^a,b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Universite Mentouri Constantine   (Algeria)

Author keywords

Neural networks; Potential target; Psychiatry; Therapeutical implication

Indexed keywords

ANTIDEPRESSANT AGENT;

CHINESE MEDICINE; DRUG EFFICACY; DRUG RESEARCH; HUMAN; MENTAL DISEASE; NERVE CELL NETWORK; NERVOUS SYSTEM DEVELOPMENT; NEUROPHARMACOLOGY; PATHOPHYSIOLOGY; REVIEW;

EID: 84901742216     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2013.01.008     Document Type: Review

References (91)

1. Adamson P., Mantzouridis T., Xiang J.Z., Hajimohammadreza I., Brammer M.J., Campbell I.C. Alpha 2-adrenergic, kappa-opiate, and P1-purinergic autoreceptors have mutually antagonistic effects: a new regulatory mechanism?. J. Neurochem. 1989, 53(4):1077-1082.
2. Aldrich J.V., Patkar K.A., McLaughlin J.P. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc. Natl. Acad. Sci. USA 2009, 106(43):18396-18401.
3. Allgaier C., Daschmann B., Sieverling J., Hertting G. Presynaptic kappa-opioid receptors on noradrenergic nerve terminals couple to G proteins and interact with the alpha 2-adrenoceptors. J. Neurochem. 1989, 53(5):1629-1635.
4. Alwan S., Friedman J.M. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009, 23(6):493-509.
5. Andersen S.L. Trajectories of brain development: point of vulnerability or window of opportunity?. Neurosci. Biobehav. Rev. 2003, 27(1-2):3-18.
6. Bals-Kubik R., Herz A., Shippenberg T.S. Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology (Berl) 1989, 98(2):203-206.
7. Barrett A.C., Smith E.S., Picker M.J. Sex-related differences in mechanical nociception and antinociception produced by mu- and kappa-opioid receptor agonists in rats. Eur. J. Pharmacol. 2002, 452(2):163-173.
8. Beardsley P.M., Howard J.L., Shelton K.L., Carroll F.I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 2005, 183(1):118-126.
9. Benmansour S., Cecchi M., Morilak D.A., Gerhardt G.A., Javors M.A., Gould G.G., Frazer A. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J. Neurosci. 1999, 19(23):10494-10501.
10. Bodkin J.A., Zornberg G.L., Lukas S.E., Cole J.O. Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol. 1995, 15(1):49-57.
11. Borue X., Chen J., Condron B.G. Developmental effects of SSRIs: lessons learned from animal studies. Int. J. Dev. Neurosci. 2007, 25(6):341-347.
12. Bremner J.D., Elzinga B., Schmahl C., Vermetten E. Structural and functional plasticity of the human brain in posttraumatic stress disorder. Prog. Brain Res. 2008, 167:171-186.
13. Brezun J.M., Daszuta A. Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats. Neuroscience 1999, 89(4):999-1002.
14. Bridge J.A., Iyengar S., Salary C.B., Barbe R.P., Birmaher B., Pincus H.A., Ren L., Brent D.A. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297(15):1683-1696.
15. Bruchas M.R., Land B.B., Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010, 1314:44-55.
16. Bucheler R., Gleiter C.H., Schwoerer P., Gaertner I. Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage). Pharmacopsychiatry 2005, 38(1):1-5.
17. Carlezon W.A., Beguin C., Knoll A.T., Cohen B.M. Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol. Ther. 2009, 123(3):334-343.
18. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. science 2003, 301(5631):386-389.
19. Catapano L.A., Manji H.K. G protein-coupled receptors in major psychiatric disorders. Biochim. Biophys. Acta 2007, 1768(4):976-993.
20. Chappell P.B., Leckman J.F., Scahill L.D., Hardin M.T., Anderson G., Cohen D.J. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: a pilot study. Psychiatry Res. 1993, 47(3):267-280.
21. Chartoff E., Sawyer A., Rachlin A., Potter D., Pliakas A., Carlezon W.A. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology 2012, 62(1):167-176.
22. Cipriani A., Geddes J.R., Furukawa T.A., Barbui C. Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can. J. Psychiatry 2007, 52(9):553-562.
23. Cohen B.M., Murphy B. The effects of pentazocine, a kappa agonist, in patients with mania. Int. J. Neuropsychopharmacol. 2008, 11(2):243-247.
24. Conrad C.D. Chronic stress-induced hippocampal vulnerability: the glucocorticoid vulnerability hypothesis. Rev. Neurosci. 2008, 19(6):395-411.
25. De Vry J. 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berl) 1995, 121(1):1-26.
26. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 1988, 85(14):5274-5278.
27. Dion A.M., Sanderson S.C., Murrin L.C., Bevins R.A. Diminished conditioned responding to the nicotine stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine transporter. Pharmacol. Biochem. Behav. 2012, 100(3):419-424.
28. Donzanti B.A., Althaus J.S., Payson M.M., Von Voigtlander P.F. Kappa agonist-induced reduction in dopamine release: site of action and tolerance. Res. Commun. Chem. Pathol. Pharmacol. 1992, 78(2):193-210.
29. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007, 64(3):327-337.
30. Ford C.P., Mark G.P., Williams J.T. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J. Neurosci. 2006, 26(10):2788-2797.
31. Frazer A. Pharmacology of antidepressants. J. Clin. Psychopharmacol. 1997, 17 Suppl 1:2S-18S.
32. Ghanemi A., He L., Yan M. New factors influencing G protein coupled receptors' system functions. Alex. J. Med. 2013, 49(1):1-5.
33. Gould E., Cameron H.A., Daniels D.C., Woolley C.S., McEwen B.S. Adrenal hormones suppress cell division in the adult rat dentate gyrus. J. Neurosci. 1992, 12(9):3642-3650.
34. Hammad T.A., Laughren T., Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 2006, 63(3):332-339.
35. Hill M.N., Gorzalka B.B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol. Disord. Drug Targets 2009, 8(6):451-458.
36. Hirschfeld R.M. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 2000, 61 Suppl 6:4-6.
37. Holmes A. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci. Biobehav. Rev. 2008, 32(7):1293-1314.
38. Homberg J.R., Olivier J.D., Blom T., Arentsen T., van Brunschot C., Schipper P., Korte-Bouws G., van Luijtelaar G., Reneman L. Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One 2011, 6(1):e16646.
39. Jackson K.J., Carroll F.I., Negus S.S., Damaj M.I. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology (Berl) 2010, 210(2):285-294.
40. Jin Z.L., Gao N., Zhou D., Chi M.G., Yang X.M., Xu J.P. The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor. Pharmacol. Biochem. Behav. 2012, 100(3):431-439.
41. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 1992, 12(2):483-488.
42. Klomp A., Tremoleda J.L., Wylezinska M., Nederveen A.J., Feenstra M., Gsell W., Reneman L. Lasting effects of chronic fluoxetine treatment on the late developing rat brain: age-dependent changes in the serotonergic neurotransmitter system assessed by pharmacological MRI. Neuroimage 2012, 59(1):218-226.
43. Knoll A.T., Meloni E.G., Thomas J.B., Carroll F.I., Carlezon W.A. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J. Pharmacol. Exp. Ther. 2007, 323(3):838-845.
44. Koch S., Perry K.W., Nelson D.L., Conway R.G., Threlkeld P.G., Bymaster F.P. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 2002, 27(6):949-959.
45. Kreek M.J., Koob G.F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998, 51(1-2):23-47.
46. Krishnan V., Nestler E.J. Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry 2010, 167(11):1305-1320.
47. Land B.B., Bruchas M.R., Lemos J.C., Xu M., Melief E.J., Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J. Neurosci. 2008, 28(2):407-414.
48. LeDoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 2000, 23:155-184.
49. Leone P., Pocock D., Wise R.A. Morphine-dopamine interaction: ventral tegmental morphine increases nucleus accumbens dopamine release. Pharmacol. Biochem. Behav. 1991, 39(2):469-472.
50. Li Q., Luo T., Jiang X., Wang J. Anxiolytic effects of 5-HTA receptors and anxiogenic effects of 5-HTC receptors in the amygdala of mice. Neuropharmacology 2012, 62(1):474-484.
51. Lopez-Munoz F., Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr. Pharm. Des. 2009, 15(14):1563-1586.
52. Machado S., Paes F., Velasques B., Teixeira S., Piedade R., Ribeiro P., Nardi A.E., Arias-Carrion O. Is rTMS an effective therapeutic strategy that can be used to treat anxiety disorders?. Neuropharmacology 2012, 62(1):125-134.
53. Mague S.D., Pliakas A.M., Todtenkopf M.S., Tomasiewicz H.C., Zhang Y., Stevens W.C., Jones R.M., Portoghese P.S., Carlezon W.A. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 2003, 305(1):323-330.
54. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20(24):9104-9110.
55. Mansour A., Watson S.J., Akil H. Opioid receptors: past, present and future. Trends Neurosci. 1995, 18(2):69-70.
56. Markou A., Kosten T.R., Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 1998, 18(3):135-174.
57. McEwen B.S. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 2000, 886(1-2):172-189.
58. McLaughlin J.P., Marton-Popovici M., Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J. Neurosci. 2003, 23(13):5674-5683.
59. Mourilhe P., Stokes P.E. Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression. Drug Saf. 1998, 18(1):57-82.
60. Murray M.L., Wong I.C., de Vries C.S. Treating major depression in children and adolescents: research is needed into safer and more effective drugs. BMJ 2004, 328(7438):524-525.
61. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59(12):1151-1159.
62. Newton S.S., Thome J., Wallace T.L., Shirayama Y., Schlesinger L., Sakai N., Chen J., Neve R., Nestler E.J., Duman R.S. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J. Neurosci. 2002, 22(24):10883-10890.
63. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry 2006, 63(8):898-906.
64. Petrik D., Lagace D.C., Eisch A.J. The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building?. Neuropharmacology 2012, 62(1):21-34.
65. Pfeiffer A., Brantl V., Herz A., Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. science 1986, 233(4765):774-776.
66. Pliakas A.M., Carlson R.R., Neve R.L., Konradi C., Nestler E.J., Carlezon W.A. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J. Neurosci. 2001, 21(18):7397-7403.
67. Prediger R.D., Matheus F.C., Schwarzbold M.L., Lima M.M., Vital M.A. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology 2012, 62(1):115-124.
68. Racagni G., Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin. Neurosci. 2008, 10(4):385-400.
69. Ressler K.J., Mayberg H.S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat. Neurosci. 2007, 10(9):1116-1124.
70. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. science 1987, 237(4819):1219-1223.
71. Roozendaal B., McEwen B.S., Chattarji S. Stress, memory and the amygdala. Nat. Rev. Neurosci. 2009, 10(6):423-433.
72. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry 2000, 57(10):925-935.
73. Schule C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J. Neuroendocrinol. 2007, 19(3):213-226.
74. Sheline Y.I., Mittler B.L., Mintun M.A. The hippocampus and depression. Eur. Psychiatry 2002, 17 Suppl 3:300-305.
75. Shippenberg T.S., Zapata A., Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacol. Ther. 2007, 116(2):306-321.
76. Smith M.A., French A.M. Age-related differences in sensitivity to the antinociceptive effects of kappa opioids in adult male rats. Psychopharmacology (Berl) 2002, 162(3):255-264.
77. Snyder S.H., Pasternak G.W. Historical review: opioid receptors. Trends Pharmacol. Sci. 2003, 24(4):198-205.
78. Spanagel R., Herz A., Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. USA 1992, 89(6):2046-2050.
79. Todtenkopf M.S., Marcus J.F., Portoghese P.S., Carlezon W.A. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) 2004, 172(4):463-470.
80. Valentino R.J., Reyes B., Van Bockstaele E., Bangasser D. Molecular and cellular sex differences at the intersection of stress and arousal. Neuropharmacology 2012, 62(1):13-20.
81. Vergne D.E., Nemeroff C.B. The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression. Curr. Psychiatry Rep. 2006, 8(6):452-457.
82. Wadenberg M.L. A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist. CNS Drug Rev. 2003, 9(2):187-198.
83. Walker B.M., Koob G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008, 33(3):643-652.
84. Walsh S.L., Geter-Douglas B., Strain E.C., Bigelow G.E. Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J. Pharmacol. Exp. Ther. 2001, 299(1):147-158.
85. Walsh S.L., Strain E.C., Abreu M.E., Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 2001, 157(2):151-162.
86. Wee S., Orio L., Ghirmai S., Cashman J.R., Koob G.F. Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology (Berl) 2009, 205(4):565-575.
87. Wilens T.E., Cohen L., Biederman J., Abrams A., Neft D., Faird N., Sinha V. Fluoxetine pharmacokinetics in pediatric patients. J. Clin. Psychopharmacol. 2002, 22(6):568-575.
88. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 1987, 94(4):469-492.
89. Wohlfarth T.D., van Zwieten B.J., Lekkerkerker F.J., Gispen-de Wied C.C., Ruis J.R., Elferink A.J., Storosum J.G. Antidepressants use in children and adolescents and the risk of suicide. Eur. Neuropsychopharmacol. 2006, 16(2):79-83.
90. Zito J.M., Safer D.J., DosReis S., Gardner J.F., Soeken K., Boles M., Lynch F. Rising prevalence of antidepressants among US youths. Pediatrics 2002, 109(5):721-727.
91. Zlomuzica A., Viggiano D., Degen J., Binder S., Ruocco L.A., Sadile A.G., Willecke K., Huston J.P., Dere E. Behavioral alterations and changes in Ca/calmodulin kinase II levels in the striatum of connexin36 deficient mice. Behav. Brain Res. 2012, 226(1):293-300.